ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2013

Abstract Number: 2518

Only BAFF mRNA, Not BAFF Protein Level In Blood, Is Associated With SLE Activity Over One Year

Eric Zollars1, Hong Fang2, Jadwiga Bienkowska3, Julie Czerkowicz4, Ann Ranger4, Norm Allaire5, Alice Thai4, Jeff Browning6, Laurence S. Magder7 and Michelle Petri2, 1Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Translational Medicine, Biogen Idec Inc., Cambridge, MA, 4Biogen Idec Inc, Cambridge, MA, 5Biogen Idec Inc., Cambridge, MA, 6Boston University School of Medicine, Boston, MA, 7Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: BAFF, Disease Activity and systemic lupus erythematosus (SLE)

Session Information

Title: Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications

Session Type: Abstract Submissions (ACR)

Background/Purpose: B-cell–activating factor (BAFF; also known as B lymphocyte stimulator or BLyS) is a prominent factor in the selection and survival of B cells. BAFF has been demonstrated to be elevated in the blood of systemic lupus erythematosus (SLE) patients and is implicated in the pathogenesis of the disease.  We have shown that BAFF gene expression level (mRNA) in whole blood associates with same day disease activity and predicts future activity in SLE patients.  The concentration of the BAFF protein in serum has also been used as a marker of disease activity. In this study, we investigated the utility of BAFF mRNA versus protein level as a predictor of future global disease activity in SLE patients. 

Methods: 292 patients (59% Caucasian, 34% African-American, 92% female, mean age 46 ±12 years) were enrolled in a prospective observational study. At baseline, BAFF gene expression level was measured in peripheral blood RNA (PAXgene) using microarray (Affymetrix) and confirmed with quantitative PCR.  Serum BAFF (protein) levels were measured using the Rules Based Medicine platform.  The number of visits per patient over the following year ranged from 1-9. Six patients had 1 visit, 46 patients had 2-3 visits, 159 patients had 4 visits, and 81 patients had more than 4 visits. P-values were calculated using generalized estimating equations as implemented in SAS 9.2. P-values were then adjusted for ethnicity.

Results:

Table 1 shows the association of BAFF mRNA with SLE global activity (physician global assessment, PGA; and SLEDAI) over the next year, as well as renal activity, serologies and ESR over the next year. Table 2 shows the association of BAFF protein with the same disease parameters.

Table 1: Association of baseline BAFF mRNA level with percentage of visits with disease activity over the subsequent year

 

Variable

Low BAFF (<10.7)

N visits=387

Med BAFF (10.7-11.4) N visits=476

High BAFF (>11.4)

N visits=347

Adjusted P-value for ethnicity

Physician global assessment >1

8%

21%

24%

0.0041

SLEDAI ≥2

36%

57%

71%

<0.0001

Urine Protein/Creatinine Ratio (≥0.5)

3%

13%

13%

0.0096

Anti-dsDNA ≥ 10

9%

21%

35%

<0.0001

C3 <79 mg/dL

4%

11%

21%

0.0004

C4 <12 mg/dL

4%

11%

19%

0.0005

ESR >20

35%

55%

63%

0.0005

Table 2: Association of baseline BAFF protein level with percentage of visits with disease activity over the subsequent year

 

Variable

Low (<950 pg/ml)

N patients=96

N visits=405

Med (950-1400 pg/ml)

N patients=98

N visits=404

High (>1400 pg/ml)

N patients=98

N visits=401

P-value

Adjusted P-value for ethnicity

Physician global assessment >1

17%

15%

21%

0.49

0.53

SLEDAI ≥2

51%

52%

60%

0.30

0.073

Urine Protein/Creatinine Ratio (≥0.5)

9%

7%

12%

0.39

0.38

Anti-dsDNA ≥ 10

18%

14%

32%

0.0036

0.0031

C3 <79 mg/dL

7%

10%

18%

0.052

0.090

C4 <12 mg/dL

9%

7%

16%

0.090

0.14

ESR >20

45%

51%

55%

0.25

0.11

Conclusion: BAFF mRNA at the baseline visit was strongly associated with global disease activity, urine protein/creatinine ≥0.5, serologies, and ESR over the next year. In contrast, BAFF protein level in the blood at baseline only correlated with anti-dsDNA over the next year. This study supports the use of BAFF mRNA level in peripheral blood rather than protein as a predictive biomarker of disease activity in SLE patients.


Disclosure:

E. Zollars,
None;

H. Fang,
None;

J. Bienkowska,

Biogen Idec Inc,

1,

Biogen Idec Inc,

3;

J. Czerkowicz,

Biogen Idec Inc,

1,

Biogen Idec Inc,

3;

A. Ranger,

Biogen Idec Inc,

1,

Biogen Idec Inc,

3;

N. Allaire,

Biogen Idec Inc,

1,

Biogen Idec Inc,

3;

A. Thai,

Biogen Idec Inc,

1,

Biogen Idec Inc,

3;

J. Browning,
None;

L. S. Magder,
None;

M. Petri,

Biogen Idec Inc,

2,

Biogen Idec Inc,

5.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/only-baff-mrna-not-baff-protein-level-in-blood-is-associated-with-sle-activity-over-one-year/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology